Klaria Pharma Holding: A punch in the face for migraines - Redeye

Redeye initiates coverage of Klaria Pharma Holding AB, a Swedish biotech company, utilising its transmucoadhesive drug delivery technology platform to offer efficient and reliable treatments. We view the current share price as attractive for a significant long-term upside as we believe Klaria has the potential to provide next-generation drug delivery.

Länk till analysen i sin helhet: https://www.redeye.se/research/891246/klaria-pharma-holding-a-punch-in-the-face-for-migraines?utm_source=finwire&utm_medium=RSS